To enhance the robustness of our findings, validation with larger gene panels, including genes involved in cell cycle regulation (CDKN2A and RB1), chromatin remodeling (KDM6A, ARID1A, and STAG2), DNA repair (ERCC2), tumor suppression (MTAP), and metabolic pathways (PPARG), as well as expanded cohorts, is warranted. This evidence concerns the gene ARID1A and neoplasm.